RNAi Single Clones

MISSION® shRNA Clones for Optimal Gene Knockdown
Long term, stable gene silencing distinguishes short hairpin RNA constructs (shRNA) from other RNAi and CRISPR tools and can offer distinct advantages over knockout gene experiments. Sigma-Aldrich® Advanced Genomics, in collaboration with the Broad Institute’s RNAi consortium (TRC) scientists, have generated the most comprehensive and validated series of vectors and clones for your RNAi experiments. Take advantage of our world-class expertise in high-throughput lentiviral manufacturing and DNA purification services, which can save you time and resources. Flexible customization offerings ensure all your experimental needs are met and offers unparalleled gene coverage.
With over 350 years of technical leadership, Sigma-Aldrich® Advanced Genomics products come with expertise that extends Beyond the Bench—from discovery to therapeutic impact.
Products
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Page 41
- Page 42
- Page 43
- Page 44
- Page 45
- Page 46
- Page 47
- Page 48
- Page 49
- Page 50
- Page 51
- Page 52
- Page 53
- Page 54
- Page 55
- Page 56
- Page 57
- Page 58
- Page 59
- Page 60
- Page 61
- Page 62
- Page 63
- Page 64
- Page 65
- Page 66
- Page 67
- Page 68
- Page 69
- Page 70
- Page 71
- Page 72
- Page 73
- Page 74
- Page 75
- Page 76
- Page 77
- Page 78
- Page 79
- Page 80
- Page 81
- Page 82
- Page 83
- Page 84
- Page 85
- Page 86
- Page 87
- Page 88
- Page 89
- Page 90
- Page 91
- Page 92
- Page 93
- Page 94
- Page 95
- Page 96
- Page 97
- Page 98
- Page 99
- Page 100
- Page 101
- Page 102
- Page 103
- Page 104
- Page 105
- Page 106
- Page 107
- Page 108
- Page 109
- Page 110
- Page 111
- Page 112
- Page 113
- Page 114
- Page 115
- Page 116
- Page 117
- Page 118
- Page 119
- Page 120
- Page 121
- Page 122
- Page 123
- Page 124
- Page 125
- Page 126
- Page 127
- Page 128
- Page 129
- Page 130
- Page 131
- Page 132
- Page 133
- Page 134
- Page 135
- Page 136
- Page 137
- Page 138
- Page 139
- Page 140
- Page 141
- Page 142
- Page 143
- Page 144
- Page 145
- Page 146
- Page 147
- Page 148
- Page 149
- Page 150
- Page 151
- Page 152
- Page 153
- Page 154
- Page 155
- Page 156
- Page 157
- Page 158
- Page 159
- Page 160
- Page 161
- Page 162
- Page 163
- Page 164
- Page 165
- Page 166
- Page 167
- Page 168
- Page 169
- Page 170
- Page 171
- Page 172
- Page 173
- Page 174
- Page 175
- Page 176
- Page 177
- Page 178
- Page 179
- Page 180
- Page 181
- Page 182
- Page 183
- Page 184
- Page 185
- Page 186
- Page 187
- Page 188
- Page 189
- Page 190
- Page 191
- Page 192
- Page 193
- Page 194
- Page 195
- Page 196
- Page 197
- Page 198
- Page 199
- Page 200
- Page 201
- Page 202
- Page 203
- Page 204
- Page 205
- Page 206
- Page 207
- Page 208
- Page 209
- Page 210
- Page 211
- Page 212
- Page 213
- Page 214
- Page 215
- Page 216
- Page 217
- Page 218
- Page 219
- Page 220
- Page 221
- Page 222
- Page 223
- Page 224
- Page 225
- Page 226
- Page 227
- Page 228
- Page 229
- Page 230
- Page 231
- Page 232
- Page 233
- Page 234
- Page 235
- Page 236
- Page 237
- Page 238
- Page 239
- Page 240
- Page 241
- Page 242
- Page 243
- Page 244
- Page 245
- Page 246
- Page 247
- Page 248
- Page 249
- Page 250
- Page 251
- Page 252
- Page 253
- Page 254
- Page 255
- Page 256
- Page 257
- Page 258
- Page 259
- Page 260
- Page 261
- Page 262
- Page 263
- Page 264
- Page 265
- Page 266
- Page 267
- Page 268
- Page 269
- Page 270
- Page 271
- Page 272
- Page 273
- Page 274
- Page 275
- Page 276
- Page 277
- Page 278
- Page 279
- Page 280
- Page 281
- Page 282
- Page 283
- Page 284
- Page 285
- Page 286
- Page 287
- Page 288
- Page 289
- Page 290
- Page 291
- Page 292
- Page 293
- Page 294
- Page 295
- Page 296
- Page 297
- Page 298
- Page 299
- Page 300
- Page 301
- Page 302
- Page 303
- Page 304
- Page 305
- Page 306
- Page 307
- Page 308
- Page 309
- Page 310
- Page 311
- Page 312
- Page 313
- Page 314
- Page 315
- Page 316
- Page 317
- Page 318
- Page 319
- Page 320
- Page 321
- Page 322
- Page 323
- Page 324
- Page 325
- Page 326
- Page 327
- Page 328
- Page 329
- Page 330
- Page 331
- Page 332
- Page 333
- Page 334
- Page 335
- Page 336
- Page 337
- Page 338
- Page 339
- Page 340
- Page 341
- Page 342
- Page 343
- Page 344
- Page 345
- Page 346
- Page 347
- Page 348
- Page 349
- Page 350
- Page 351
- Page 352
- Page 353
- Page 354
- Page 355
- Page 356
- Page 357
- Page 358
- Page 359
- Page 360
- Page 361
- Page 362
- Page 363
- Page 364
- Page 365
- Page 366
- Page 367
- Page 368
- Page 369
- Page 370
- Page 371
- Page 372
- Page 373
- Page 374
- Page 375
- Page 376
- Page 377
- Page 378
- Page 379
- Page 380
- Page 381
- Page 382
- Page 383
- Page 384
- Page 385
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Page 41
- Page 42
- Page 43
- Page 44
- Page 45
- Page 46
- Page 47
- Page 48
- Page 49
- Page 50
- Page 51
- Page 52
- Page 53
- Page 54
- Page 55
- Page 56
- Page 57
- Page 58
- Page 59
- Page 60
- Page 61
- Page 62
- Page 63
- Page 64
- Page 65
- Page 66
- Page 67
- Page 68
- Page 69
- Page 70
- Page 71
- Page 72
- Page 73
- Page 74
- Page 75
- Page 76
- Page 77
- Page 78
- Page 79
- Page 80
- Page 81
- Page 82
- Page 83
- Page 84
- Page 85
- Page 86
- Page 87
- Page 88
- Page 89
- Page 90
- Page 91
- Page 92
- Page 93
- Page 94
- Page 95
- Page 96
- Page 97
- Page 98
- Page 99
- Page 100
- Page 101
- Page 102
- Page 103
- Page 104
- Page 105
- Page 106
- Page 107
- Page 108
- Page 109
- Page 110
- Page 111
- Page 112
- Page 113
- Page 114
- Page 115
- Page 116
- Page 117
- Page 118
- Page 119
- Page 120
- Page 121
- Page 122
- Page 123
- Page 124
- Page 125
- Page 126
- Page 127
- Page 128
- Page 129
- Page 130
- Page 131
- Page 132
- Page 133
- Page 134
- Page 135
- Page 136
- Page 137
- Page 138
- Page 139
- Page 140
- Page 141
- Page 142
- Page 143
- Page 144
- Page 145
- Page 146
- Page 147
- Page 148
- Page 149
- Page 150
- Page 151
- Page 152
- Page 153
- Page 154
- Page 155
- Page 156
- Page 157
- Page 158
- Page 159
- Page 160
- Page 161
- Page 162
- Page 163
- Page 164
- Page 165
- Page 166
- Page 167
- Page 168
- Page 169
- Page 170
- Page 171
- Page 172
- Page 173
- Page 174
- Page 175
- Page 176
- Page 177
- Page 178
- Page 179
- Page 180
- Page 181
- Page 182
- Page 183
- Page 184
- Page 185
- Page 186
- Page 187
- Page 188
- Page 189
- Page 190
- Page 191
- Page 192
- Page 193
- Page 194
- Page 195
- Page 196
- Page 197
- Page 198
- Page 199
- Page 200
- Page 201
- Page 202
- Page 203
- Page 204
- Page 205
- Page 206
- Page 207
- Page 208
- Page 209
- Page 210
- Page 211
- Page 212
- Page 213
- Page 214
- Page 215
- Page 216
- Page 217
- Page 218
- Page 219
- Page 220
- Page 221
- Page 222
- Page 223
- Page 224
- Page 225
- Page 226
- Page 227
- Page 228
- Page 229
- Page 230
- Page 231
- Page 232
- Page 233
- Page 234
- Page 235
- Page 236
- Page 237
- Page 238
- Page 239
- Page 240
- Page 241
- Page 242
- Page 243
- Page 244
- Page 245
- Page 246
- Page 247
- Page 248
- Page 249
- Page 250
- Page 251
- Page 252
- Page 253
- Page 254
- Page 255
- Page 256
- Page 257
- Page 258
- Page 259
- Page 260
- Page 261
- Page 262
- Page 263
- Page 264
- Page 265
- Page 266
- Page 267
- Page 268
- Page 269
- Page 270
- Page 271
- Page 272
- Page 273
- Page 274
- Page 275
- Page 276
- Page 277
- Page 278
- Page 279
- Page 280
- Page 281
- Page 282
- Page 283
- Page 284
- Page 285
- Page 286
- Page 287
- Page 288
- Page 289
- Page 290
- Page 291
- Page 292
- Page 293
- Page 294
- Page 295
- Page 296
- Page 297
- Page 298
- Page 299
- Page 300
- Page 301
- Page 302
- Page 303
- Page 304
- Page 305
- Page 306
- Page 307
- Page 308
- Page 309
- Page 310
- Page 311
- Page 312
- Page 313
- Page 314
- Page 315
- Page 316
- Page 317
- Page 318
- Page 319
- Page 320
- Page 321
- Page 322
- Page 323
- Page 324
- Page 325
- Page 326
- Page 327
- Page 328
- Page 329
- Page 330
- Page 331
- Page 332
- Page 333
- Page 334
- Page 335
- Page 336
- Page 337
- Page 338
- Page 339
- Page 340
- Page 341
- Page 342
- Page 343
- Page 344
- Page 345
- Page 346
- Page 347
- Page 348
- Page 349
- Page 350
- Page 351
- Page 352
- Page 353
- Page 354
- Page 355
- Page 356
- Page 357
- Page 358
- Page 359
- Page 360
- Page 361
- Page 362
- Page 363
- Page 364
- Page 365
- Page 366
- Page 367
- Page 368
- Page 369
- Page 370
- Page 371
- Page 372
- Page 373
- Page 374
- Page 375
- Page 376
- Page 377
- Page 378
- Page 379
- Page 380
- Page 381
- Page 382
- Page 383
- Page 384
- Page 385
Expert Gene Knockdown You Can Count On
As the exclusive provider of the trusted TRC1.5 and TRC2 collections, our comprehensive MISSION® shRNA product offering consists of almost 200,000 pre-cloned shRNA constructs targeting more than 20,000 human and mouse genes. Easily search by your gene of interest, view validation data, and order in a few simple clicks. shRNA clones are available in lentivirus, plasmid DNA, or bacterial stocks.
Each gene is represented by multiple vector constructs targeting different regions of the gene sequence. Every shRNA is cloned into the pLKO.1 lentiviral vector, and is sequence verified to ensure a match to the target gene. Sigma-Aldrich® Advanced Genomics offers the most trusted and comprehensive shRNA screening portfolio for even the most difficult targets and cell lines.
RNAi Screening for Genome-Wide Knockdown
Functional genomics screens are an integral part of discovery research, allowing scientists to unravel the mechanisms underlying biological systems, pathways, and diseases. Effective interrogation of these complex molecular interaction networks requires shRNA libraries that deliver reliable, efficient, and long-term knockdown.
shRNA VECTORS & CONTROLS
Optimized experimental designs start with the right vector and controls. Shop our comprehensive offering of vector options and positive and negative controls for TRC1.5 and TRC2 available in plasmid DNA or lentiviral transduction particles.
Custom Cloning
Whether you need a vector with a fluorophore tag, alternate promoters, or higher viral titers, our collection has you covered. Our primary backbones are the TRC-designed pLKO.1-puro and TRC2-pLKO.5-puro vectors. These vectors can be adapted to meet your needs for any experiment.
We're Here to Help
Whether you need help designing your experiment, need a custom vector, high viral titer, require assistance troubleshooting, or simply want to better understand how you can apply shRNA gene silencing in your research, Sigma-Aldrich® Advanced Genomics is here to guide you.
MISSION® shRNA Knockdown Guarantee
Sigma-Aldrich® shRNA is guaranteed that upon purchase of the defined lentiviral clone set quantity on the shRNA product page for your gene of interest (this varies, but is typically 5 clones), at least one of those lentiviral clones for a gene should yield greater than 70% knockdown.*
Related Resources
- Molecular Essentials Guide
Learn how our comprehensive molecular tools and reagents provide precise, ready-to-use solutions for your workflows.
- Getting Started with MISSION® shRNA
RNA interference and siRNAs for gene silencing in molecular biology studies.
- pLKO-1 Vector and shRNA Design Frequently Asked Questions
Frequently asked questions about pLKO-1 vector & shRNA design
- Next-Gen RNA Interference with MISSION® shRNA
RNAi technology advancements enable gene expression silencing through endogenous RNAi pathways, applicable across eukaryotes.
- MISSION® Application Data
We are committed to providing you with helpful application notes and data for the MISSION® TRC shRNA libraries.
- MISSION® FAQs
We answer your frequently asked questions about shRNA including available formats, experimental design and analysis, advanced applications, ordering, custom options and much more.
- Pooled Lentiviral shRNA Screens to Identify Essential Cancer Pathways
Presenting an article on Pooled Lentiviral shRNA Screens to Identify Essential Cancer Pathways.
- Brochure: MISSION® RNAi Tools
Depend on our comprehensive shRNA & miRNA portfolio.
- Vector Maps
A series of vectors to enable a successful implementation of your RNAi experiments.
- General shRNA FAQs
We answers your frequently asked questions about shRNA, the TRC. MISSION and more.
- Lentiviral Transduction Protocol
Detailed procedure for how to perform a lentiviral transduction of MISSION shRNA lentiviral particles to achieve a stable long term silencing and phenotypic change.
- Advanced RNAi Applications — Difficult Cell Types FAQs
We answer your frequently asked questions about using shRNA with difficult cell types.
- shRNA Gene Families Sets
MISSION® shRNA Library gene sets mapped by Bioinformatics team for specific cellular pathways.
- MISSION® Lentiviral Controls
When conducting shRNA experiments, proper controls are a key element of experimental design. Proper use of controls permits accurate interpretation of knockdown results and provides assurance of the specificity of the observed phenotype. We offer a variety of positive, negative, and transduction controls to meet these needs.
- Vector Maps
A series of vectors to enable a successful implementation of your RNAi experiments.
*This guarantee does not apply to transient transfections with DNA. Proper controls and conditions are required to go along with supporting data showing ineffective knock-down for the guarantee to apply. Appropriate supporting data would include quantitative PCR-based silencing data, comparing target mRNA levels of an appropriate positive control shRNA to an appropriate negative control shRNA, demonstrating knockdown of the target mRNA greater than or equal to 70%. Due to the variability of antibodies and protein half-lives, we are unable to accept protein-based detection methods. In the case that there are no more shRNA for that gene target, or all shRNA fail to knock down the target gene by 70% or more, we will refund the price for the clone set quantity.
To continue reading please sign in or create an account.
Don't Have An Account?